==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1849 details
Primary information
ThPP IDTh1237
Therapeutic Peptide/Protein NameSomatropin recombinant
SequenceFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT view full sequnce in fasta
Functional ClassificationIb
Molecular Weight22129
Chemical FormulaC990H1532N262O300S7
Isoelectric Point5.27
Hydrophobicity-0.411
Melting Point (℃)76 °C at
Half LifeNA
DescriptionRecombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli
Indication/DiseaseFor treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss
PharmacodynamicsUsed in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).
Mechanism of ActionhGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
Clearance2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]
CategoriesHormones, Hormone Substitutes, and Hormone Antagonists
Patents NumberCA1326439,CA2252535
Date of IssueMostly fro
Date of ExpiryMostly 202
Drug InteractionThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Bazedoxifene, Chlorotrianisene, Conjugated Equine Estrogens, Cortisone acetate, Dienestrol, Diethylstilbestrol, Estradiol, Estriol, Estrone, Ethinyl Estradiol.
TargetGrowth hormone receptor, Prolactin receptor
Information of corresponding available drug in the market
Brand NameBioTropin
CompanyBiotech General
Brand DiscriptionBitropin is a recombinant human growth hormone
Prescribed forIt is indicate dfor short stature due to pitutary growth hormone deficency, turner Syndorme, Children suffering from renal insuuficiency.
Chemical NameNA
FormulationNA
Physcial AppearncePowder and Solvent for Solution
Route of AdministrationSubcutaneous
Recommended DosageThe reequired dose is 10mg/ml
Contraindicationchildren with closed epiphyses.
Side Effectsmay lead to loss or increase of adipose tissue as well as punctual haemorrhage and bruising at the injection site.
Useful Linkhttps://www.old.health.gov.il/units/pharmacy/trufot/alonim/Bio_Tropin_10mg_dr_1316590559720.pdf , https://www.drugbank.ca/drugs/DB00052
PubMed ID2688, 2903866, 16702112, 5675428
3-D StructureTh1237 (View) or (Download)